A. Monnereau, L. Remontet, M. Maynadié, F. Binder-foucard, A. Belot et al., Estimation nationale de l'incidence des cancers en France entre 1980 et 2012. Partie 2 -Hémopathies malignes

A. J. Cowan, C. Allen, and A. Barac, Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study, JAMA oncology, 2016.

R. De-angelis, P. Minicozzi, and M. Sant, Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000-2007: Results of EUROCARE-5 population-based study, European Journal of Cancer, vol.51, pp.2254-2268, 1990.

A. Monnereau, Z. Uhry, N. Bossard, A. Cowppli-bony, N. Voirin et al., Survie des personnes atteintes de cancer en France métropolitaine, 1989-2013. Partie 2 -Hémopathies malignes -Synthèse

O. Landgren, R. A. Kyle, and R. M. Pfeiffer, Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study, Blood, vol.113, pp.5412-5417, 2009.

O. Landgren, G. Gridley, and I. Turesson, Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States, Blood, vol.107, pp.904-906, 2006.

M. E. Vanvalkenburg, G. I. Pruitt, and I. K. Brill, Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features, Cancer Causes & Control, vol.27, pp.81-91, 2016.

T. N. Sergentanis, F. Zagouri, and G. Tsilimidos, Risk Factors for Multiple Myeloma: A Systematic Review of Meta-Analyses, Clinical Lymphoma, Myeloma & Leukemia, vol.15, pp.563-577, 2015.

C. Lemarchand, S. Tual, and N. Levêque-morlais, Cancer incidence in the AGRICAN cohort study, vol.49, pp.175-185, 2005.

L. Kachuri, M. A. Harris, J. S. Macleod, M. Tjepkema, P. A. Peters et al., Cancer risks in a population-based study of 70,570 agricultural workers: results from the Canadian census health and Environment cohort (CanCHEC), BMC Cancer, vol.17, 2017.

O. Landgren, R. Zeig-owens, and O. Giricz, Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster, JAMA oncology, 2018.

C. Perrotta, S. Kleefeld, and A. Staines, Multiple myeloma and occupation: A pooled analysis by the International Multiple Myeloma Consortium, Cancer Epidemiology, vol.37, pp.300-305, 2013.

J. Acquavella, D. Garabrant, G. Marsh, T. Sorahan, and D. L. Weed, Glyphosate epidemiology expert panel review: a weight of evidence systematic review of the relationship between glyphosate exposure and non-Hodgkin's lymphoma or multiple myeloma, Critical Reviews in Toxicology, vol.46, pp.28-43, 2016.

Y. Furukawa and J. Kikuchi, Molecular pathogenesis of multiple myeloma, International Journal of Clinical Oncology, vol.20, pp.413-422, 2015.

N. Van-nieuwenhuijzen, I. Spaan, R. Raymakers, and V. Peperzak, From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells, Cancer Research, vol.78, pp.2449-2456, 2018.

G. J. Morgan, B. A. Walker, and F. E. Davies, The genetic architecture of multiple myeloma, Nature Reviews. Cancer, vol.12, pp.335-348, 2012.

S. K. Kumar and S. V. Rajkumar, The multiple myelomas -current concepts in cytogenetic classification and therapy, Nature Reviews. Clinical Oncology, 2018.

A. Brioli, L. Melchor, M. Cavo, and G. J. Morgan, The impact of intra-clonal heterogeneity on the treatment of multiple myeloma, British Journal of Haematology, vol.165, pp.441-454, 2014.

G. Bianchi and N. C. Munshi, Pathogenesis beyond the cancer clone(s) in multiple myeloma, Blood, vol.125, pp.3049-3058, 2015.

T. Hideshima, C. Mitsiades, G. Tonon, P. G. Richardson, and K. C. Anderson, Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets, Nature Reviews. Cancer, vol.7, pp.585-598, 2007.

K. Podar, Y. T. Tai, and F. E. Davies, Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration, Blood, vol.98, pp.428-435, 2001.

P. Storti, M. Bolzoni, and G. Donofrio, Hypoxia-inducible factor (HIF)-1? suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction, Leukemia, vol.27, pp.1697-1706, 2013.

R. A. Kyle, M. A. Gertz, and T. E. Witzig, Review of 1027 patients with newly diagnosed multiple myeloma, Mayo Clinic Proceedings, vol.78, pp.21-33, 2003.

A. Palumbo and K. Anderson, Multiple myeloma, The New England Journal of Medicine, vol.364, pp.1046-1060, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01282339

B. Arnulf,

, La Revue Du Praticien, vol.63, pp.101-108, 2013.

S. Harada and G. A. Rodan, Control of osteoblast function and regulation of bone mass, Nature, vol.423, pp.349-355, 2003.

G. D. Roodman, Pathogenesis of myeloma bone disease, Leukemia, vol.23, pp.435-441, 2009.

N. Giuliani and V. Rizzoli, Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma, Leukemia & Lymphoma, vol.48, pp.2323-2329, 2007.

R. Silbermann and G. D. Roodman, Myeloma bone disease: Pathophysiology and management, Journal of Bone Oncology, vol.2, pp.59-69, 2013.

D. Toscani, M. Bolzoni, F. Accardi, F. Aversa, and N. Giuliani, The osteoblastic niche in the context of multiple myeloma, Annals of the New York Academy of Sciences, vol.1335, pp.45-62, 2015.

G. D. Roodman, Osteoblast function in myeloma, Bone, vol.48, pp.135-140, 2011.

G. Birgegård, P. Gascón, and H. Ludwig, Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY, European Journal of Haematology, vol.77, pp.378-386, 2006.

F. Silvestris, P. Cafforio, M. Tucci, and F. Dammacco, Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma, Blood, vol.99, pp.1305-1313, 2002.

C. König, M. Kleber, and G. Ihorst, Prevalence of iron overload vs iron deficiency in multiple myeloma: resembling or different from MDS--and stem cell transplant (SCT)--patients?, Clinical Lymphoma, Myeloma & Leukemia, vol.13, pp.671-680, 2013.

S. Minisola, J. Pepe, S. Piemonte, and C. Cipriani, The diagnosis and management of hypercalcaemia, Clinical research ed.), vol.350, p.2723, 2015.

C. Dumontet, C. Hulin, and M. A. Dimopoulos, A predictive model for risk of early grade ? 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial, Leukemia, vol.32, pp.1404-1413, 2018.

C. Blimark, E. Holmberg, and U. Mellqvist, Multiple myeloma and infections: a populationbased study on 9253 multiple myeloma patients, Haematologica, vol.100, pp.107-113, 2015.

B. W. Teh, S. J. Harrison, L. J. Worth, K. A. Thursky, and M. A. Slavin, Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis, European Journal of Cancer, vol.67, pp.21-37, 1990.

G. Pratt, O. Goodyear, and P. Moss, Immunodeficiency and immunotherapy in multiple myeloma, British Journal of Haematology, vol.138, pp.563-579, 2007.

B. Castella, M. Foglietta, C. Riganti, and M. Massaia, V?9V?2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression, Frontiers in Immunology, vol.9, p.1492, 2018.

G. Srkalovic, M. G. Cameron, L. Rybicki, S. R. Deitcher, K. Kattke-marchant et al., Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease, Cancer, vol.101, pp.558-566, 2004.

M. Zangari, T. Berno, F. Zhan, G. Tricot, and L. Fink, Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs, Seminars in Thrombosis and Hemostasis, vol.38, pp.768-779, 2012.

J. Auwerda, P. Sonneveld, M. De-maat, and F. Leebeek, Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma, Haematologica, vol.92, pp.279-280, 2007.

R. Pal, S. A. Monaghan, and A. C. Hassett, Immunomodulatory derivatives induce PU.1 downregulation, myeloid maturation arrest, and neutropenia, Blood, vol.115, pp.605-614, 2010.

G. Dumas, S. Merceron, and L. Zafrani,

, La Revue De Medecine Interne, vol.36, pp.588-595, 2015.

P. N. Wong, S. K. Mak, K. Y. Lo, G. M. Tong, and A. K. Wong, Acute tubular necrosis in a patient with Waldenström's macroglobulinaemia and hyperviscosity syndrome. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association, European Renal Association, vol.15, pp.1684-1687, 2000.

H. C. Kwaan, Hyperviscosity in plasma cell dyscrasias, Clinical Hemorheology and Microcirculation, vol.55, pp.75-83, 2013.

S. Kalayoglu-besisik, The use of emergency apheresis in the management of plasma cell disorders, Transfusion and Apheresis Science: Official Journal of the World Apheresis Association: Official Journal of the European Society for Haemapheresis, vol.57, pp.35-39, 2018.

P. Moreau, H. Pylypenko, and S. Grosicki, Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study, The Lancet. Oncology, vol.12, pp.431-440, 2011.

S. V. Rajkumar, M. A. Dimopoulos, and A. Palumbo, International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, The Lancet. Oncology, vol.15, pp.538-548, 2014.

R. A. Kyle, E. D. Remstein, and T. M. Therneau, Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma, The New England Journal of Medicine, vol.356, pp.2582-2590, 2007.

S. V. Rajkumar, D. Larson, and R. A. Kyle, Diagnosis of smoldering multiple myeloma, The New England Journal of Medicine, vol.365, pp.474-475, 2011.

J. T. Larsen, S. K. Kumar, A. Dispenzieri, R. A. Kyle, J. A. Katzmann et al., Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma, Leukemia, vol.27, pp.941-946, 2013.

J. Hillengass, K. Fechtner, and M. Weber, Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.28, pp.1606-1610, 2010.

E. Muchtar, S. K. Kumar, H. Magen, and M. A. Gertz, Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer, Leukemia & Lymphoma, vol.59, pp.288-299, 2018.

M. Mateos, M. Hernández, and G. P. , Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma, The New England Journal of Medicine, vol.369, pp.438-447, 2013.

M. Mateos, J. M. Lopez, and P. Rodriguez-otero, Curative Strategy for High-Risk Smoldering Myeloma (GEM-CESAR): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd, Blood, vol.130, pp.402-402, 2017.

C. C. Hofmeister, A. Chari, and Y. Cohen, Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study, Blood, vol.130, p.510, 2017.

R. A. Kyle, T. M. Therneau, and S. V. Rajkumar, Prevalence of monoclonal gammopathy of undetermined significance, The New England Journal of Medicine, vol.354, pp.1362-1369, 2006.

R. A. Kyle, D. R. Larson, and T. M. Therneau, Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance, The New England Journal of Medicine, vol.378, pp.241-249, 2018.

R. A. Kyle, B. Durie, and S. V. Rajkumar, Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management, Leukemia, vol.24, pp.1121-1127, 2010.

P. Finsinger, S. Grammatico, M. Chisini, A. Piciocchi, R. Foà et al., Clinical features and prognostic factors in solitary plasmacytoma, British Journal of Haematology, vol.172, pp.554-560, 2016.

T. Jelinek, F. Kryukov, L. Rihova, and R. Hajek, Plasma cell leukemia: from biology to treatment, European Journal of Haematology, vol.95, pp.16-26, 2015.

C. Fernández-de-larrea, R. A. Kyle, and B. Durie, Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group, Leukemia, vol.27, pp.780-791, 2013.

A. Dispenzieri and . Syndrome, Update on diagnosis, risk stratification, and management, American Journal of Hematology, vol.92, pp.814-829, 2017.

G. Fouquet, S. Guidez, and V. Richez, , 2017.

M. A. Dimopoulos, J. Hillengass, and S. Usmani, Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.33, pp.657-664, 2015.

E. Kastritis, L. A. Moulopoulos, E. Terpos, V. Koutoulidis, and M. A. Dimopoulos, The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma, Leukemia, vol.28, pp.2402-2403, 2014.

T. Derlin, K. Peldschus, and S. Münster, Comparative diagnostic performance of 18 F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation, European Radiology, vol.23, pp.570-578, 2013.

M. Cavo, E. Terpos, and C. Nanni, Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group, The Lancet Oncology, vol.18, pp.206-217, 2017.

E. Muchtar, A. Dagan, and E. Robenshtok, Bone mineral density utilization in patients with newly diagnosed multiple myeloma, Hematological Oncology, vol.35, pp.703-710, 2017.

P. R. Greipp, S. Miguel, J. Durie, and B. , International staging system for multiple myeloma, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.23, pp.3412-3420, 2005.

A. Palumbo, H. Avet-loiseau, and S. Oliva, Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.33, pp.2863-2869, 2015.

A. Palumbo, S. Bringhen, and M. Mateos, Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report, Blood, vol.125, pp.2068-2074, 2015.

N. C. Munshi, H. Avet-loiseau, and A. C. Rawstron, Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis, JAMA oncology, vol.3, pp.28-35, 2017.

S. Kumar, B. Paiva, and K. C. Anderson, International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, The Lancet. Oncology, vol.17, pp.328-346, 2016.

H. Ludwig, M. Delforge, and T. Facon, Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network, Leukemia, 2018.

P. Moreau, S. Miguel, J. Sonneveld, and P. , Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology: Official Journal of the European Society for Medical Oncology, vol.28, pp.52-61, 2017.

B. Durie, A. Hoering, and M. H. Abidi, Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial, Lancet, vol.389, pp.519-527, 2017.

E. K. Mai, U. Bertsch, and J. Dürig, Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma, Leukemia, vol.29, pp.1721-1729, 2015.

M. Cavo, L. Pantani, and A. Pezzi, Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma, Leukemia, vol.29, pp.2429-2431, 2015.

M. Attal, V. Lauwers-cances, and C. Hulin, Bortezomib, and Dexamethasone with Transplantation for Myeloma, The New England Journal of Medicine, vol.376, pp.1311-1320, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01557406

S. V. Rajkumar, S. Jacobus, and N. S. Callander, Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial, The Lancet. Oncology, vol.11, pp.29-37, 2010.

J. M. Byun, J. Lee, S. Shin, M. Kang, S. Yoon et al., Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma, Blood Research, vol.53, pp.105-109, 2018.

E. A. Stadtmauer, M. C. Pasquini, and B. Blackwell, Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 -StaMINA Trial), Blood, vol.128, p.1, 2016.

P. L. Mccarthy, S. A. Holstein, and M. T. Petrucci, Lenalidomide Maintenance After Autologous StemCell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.35, pp.3279-3289, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01697539

P. Sonneveld, I. Schmidt-wolf, and B. Van-der-holt, Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.30, pp.2946-2955, 2012.

P. Sonneveld, H. Avet-loiseau, and S. Lonial, Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group, Blood, vol.127, p.2955, 2016.

M. Cavo, M. T. Petrucci, D. Raimondo, and F. , Upfront Single Versus Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial), Blood, vol.128, p.991, 2016.

T. Facon, M. A. Dimopoulos, and A. Dispenzieri, Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma, Blood, vol.131, pp.301-310, 2018.

M. Mateos, M. A. Dimopoulos, and M. Cavo, Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma, The New England Journal of Medicine, vol.378, pp.518-528, 2018.

M. Cavo, E. Terpos, and J. Bargay, The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe, Expert Review of Hematology, vol.11, pp.219-237, 2018.

M. A. Dimopoulos, P. Moreau, and A. Palumbo, Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study, The Lancet. Oncology, vol.17, pp.27-38, 2016.

J. F. San-miguel, V. Hungria, and S. Yoon, Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. The Lancet, Oncology, vol.15, pp.1195-1206, 2014.

A. Palumbo, A. Chanan-khan, and K. Weisel, The New England Journal of Medicine, vol.375, pp.754-766, 2016.

A. Jakubowiak, M. Offidani, and B. Pégourie, Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM, Blood, vol.127, pp.2833-2840, 2016.

P. Moreau, T. Masszi, and N. Grzasko, Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma, The New England Journal of Medicine, vol.374, pp.1621-1634, 2016.

M. A. Dimopoulos, A. Oriol, and H. Nahi, The New England Journal of Medicine, vol.375, pp.1319-1331, 2016.

A. K. Stewart, S. V. Rajkumar, and M. A. Dimopoulos, Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma, The New England Journal of Medicine, vol.372, pp.142-152, 2015.

S. Lonial, M. Dimopoulos, and A. Palumbo, Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma, The New England Journal of Medicine, vol.373, pp.621-631, 2015.

S. Giralt, L. Garderet, and B. Durie, American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma, Biology of Blood and Marrow Transplantation, vol.21, pp.2039-2051, 2015.

J. Laubach, L. Garderet, and A. Mahindra, Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group, Leukemia, vol.30, p.1005, 2015.

S. Trudel, N. Lendvai, and R. Popat, Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159, Blood, vol.130, p.741, 2017.

A. D. Cohen, A. L. Garfall, and E. A. Stadtmauer, Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM), Blood, vol.130, p.505, 2017.

R. Mhaskar, A. Kumar, B. Miladinovic, and B. Djulbegovic, Bisphosphonates in multiple myeloma: an updated network meta-analysis. The Cochrane Database of, Systematic Reviews, vol.12, p.3188, 2017.

E. Terpos, M. Kleber, and M. Engelhardt, European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications, Haematologica, vol.100, pp.1254-1266, 2015.

K. Anderson, N. Ismaila, and P. J. Flynn, Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.36, pp.812-818, 2018.

J. D. Robertson, K. Nagesh, and S. N. Jowitt, Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma, British Journal of Cancer, vol.82, pp.1261-1265, 2000.

M. T. Drayson, S. Bowcock, and T. Planche, Tackling Early Morbidity and Mortality in Myeloma (TEAMM): Assessing the Benefit of Antibiotic Prophylaxis and Its Effect on Healthcare Associated Infections in 977 Patients, vol.130, pp.903-903, 2017.

P. G. Richardson, M. Delforge, and M. Beksac, Management of treatment-emergent peripheral neuropathy in multiple myeloma, Leukemia, vol.26, pp.595-608, 2012.

A. Mushtaq, V. Kapoor, and A. Latif, Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review, Critical Reviews in Oncology/Hematology, vol.125, pp.1-11, 2018.

P. Richardson, R. Schlag, and N. Khuageva, Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial, British Journal of Haematology, vol.153, pp.212-221, 2011.

J. A. Snowden, S. H. Ahmedzai, and J. Ashcroft, Guidelines for supportive care in multiple myeloma 2011, British Journal of Haematology, vol.154, pp.76-103, 2011.

L. Man, A. Morris, J. Brown, S. Palkimas, and K. Davidson, Use of direct oral anticoagulants in patients on immunomodulatory agents, Journal of Thrombosis and Thrombolysis, vol.44, pp.298-302, 2017.

S. H. Nasr, A. M. Valeri, and S. Sethi, Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies, American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, vol.59, pp.786-794, 2012.

F. Bridoux, N. Leung, and C. A. Hutchison, Diagnosis of monoclonal gammopathy of renal significance, Kidney International, vol.87, pp.698-711, 2015.

M. A. Dimopoulos, P. Sonneveld, and N. Leung, International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.34, pp.1544-1557, 2016.

M. A. Dimopoulos, E. Terpos, and A. Chanan-khan, Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.28, pp.4976-4984, 2010.

D. J. Tsakiris, V. S. Stel, and P. Finne, Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association, European Renal Association, vol.25, pp.1200-1206, 2010.

F. Evison, J. Sangha, and P. Yadav, A population-based study of the impact of dialysis on mortality in multiple myeloma, British Journal of Haematology, vol.180, pp.588-591, 2018.

S. Reule, D. J. Sexton, C. A. Solid, S. Chen, and R. N. Foley, ESRD due to Multiple Myeloma in the United States, Journal of the American Society of Nephrology: JASN, vol.27, pp.1487-1494, 2001.

K. Uttervall, A. D. Duru, and J. Lund, The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment, PloS One, vol.9, p.101819, 2014.

A. Decourt, B. Gondouin, and J. C. Delaroziere, Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis, Clinical journal of the American Society of Nephrology: CJASN, vol.11, pp.431-441, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01482660

B. Sprangers, Aetiology and management of acute kidney injury in multiple myeloma. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association, European Renal Association, vol.33, pp.722-724, 2018.

P. W. Sanders, Mechanisms of light chain injury along the tubular nephron, Journal of the American Society of Nephrology: JASN, vol.23, pp.1777-1781, 2012.

M. Leboulleux, B. Lelongt, and B. Mougenot, Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies, Kidney International, vol.48, pp.72-79, 1995.
URL : https://hal.archives-ouvertes.fr/inserm-01876779

T. Al-hussain, M. H. Hussein, A. Mana, H. Akhtar, and M. , Renal involvement in monoclonal gammopathy, Advances in Anatomic Pathology, vol.22, pp.121-134, 2015.

F. Serafini-cessi, N. Malagolini, and D. Cavallone, Tamm-Horsfall glycoprotein: biology and clinical relevance, American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, vol.42, pp.658-676, 2003.

W. Ying, C. E. Allen, L. M. Curtis, K. J. Aaron, and P. W. Sanders, Mechanism and prevention of acute kidney injury from cast nephropathy in a rodent model, The Journal of Clinical Investigation, vol.122, pp.1777-1785, 2012.

C. A. Hutchison, V. Batuman, and J. Behrens, The pathogenesis and diagnosis of acute kidney injury in multiple myeloma, Nature Reviews. Nephrology, vol.8, pp.43-51, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00696471

L. Ecotière, A. Thierry, and C. Debiais-delpech, Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association, European Renal Association, vol.31, pp.64-72, 2016.

C. Cohen, V. Javaugue, and F. Joly,

, Nephrologie & Therapeutique, vol.12, pp.131-139, 2016.

S. Déret, J. Chomilier, D. B. Huang, J. L. Preud'homme, F. J. Stevens et al., Molecular modeling of immunoglobulin light chains implicates hydrophobic residues in non-amyloid light chain deposition disease, Protein Engineering, vol.10, pp.1191-1197, 1997.

B. Kaplan, A. Livneh, and G. Gallo, Charge differences between in vivo deposits in immunoglobulin light chain amyloidosis and non-amyloid light chain deposition disease, British Journal of Haematology, vol.136, pp.723-728, 2007.

F. Bridoux, V. Javaugue, and S. Bender, Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management, Kidney International, vol.91, pp.423-434, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01567760

C. Sirac, G. A. Herrera, and P. W. Sanders, Animal models of monoclonal immunoglobulin-related renal diseases, Nature Reviews Nephrology, vol.14, pp.246-264, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01759567

S. S. Motwani, L. Herlitz, D. Monga, K. D. Jhaveri, and A. Q. Lam, of Nephrology OncoNephrology Forum. Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias, vol.11, pp.2260-2272, 2016.

S. M. Said, S. Sethi, and A. M. Valeri, Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases, Clinical journal of the American Society of Nephrology: CJASN, vol.8, pp.1515-1523, 2013.

R. S. Abraham, S. M. Geyer, and T. L. Price-troska, Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL), Blood, vol.101, pp.3801-3808, 2003.

J. A. Vrana, J. D. Gamez, B. J. Madden, J. D. Theis, H. R. Bergen et al., Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens, Blood, vol.114, pp.4957-4959, 2009.

A. Dispenzieri, M. A. Gertz, and R. A. Kyle, Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.22, pp.3751-3757, 2004.

A. Jaccard, E. Desport, D. Mohty, and F. Bridoux,

, La Revue De Medecine Interne, vol.36, pp.89-97, 2015.

N. Leung, M. E. Drosou, and S. H. Nasr, Dysproteinemias and Glomerular Disease, Clinical journal of the American Society of Nephrology: CJASN, vol.13, pp.128-139, 2018.

N. Leung, M. Gertz, and R. A. Kyle, Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases, Clinical journal of the American Society of Nephrology: CJASN, vol.7, pp.1964-1968, 2012.

N. Leung and J. Behrens, Current approach to diagnosis and management of acute renal failure in myeloma patients, Advances in Chronic Kidney Disease, vol.19, pp.297-302, 2012.

C. A. Hutchison, P. Cockwell, and S. Stringer, Early reduction of serum-free light chains associates with renal recovery in myeloma kidney, Journal of the American Society of Nephrology: JASN, vol.22, pp.1129-1136, 2011.

E. Kastritis, A. Anagnostopoulos, and M. Roussou, Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents, Haematologica, vol.92, pp.546-549, 2007.

R. Sarközi, P. Perco, and K. Hochegger, Bortezomib-induced survival signals and genes in human proximal tubular cells, The Journal of Pharmacology and Experimental Therapeutics, vol.327, pp.645-656, 2008.

C. Scheid, P. Sonneveld, and I. Schmidt-wolf, Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial, Haematologica, vol.99, pp.148-154, 2014.

M. A. Dimopoulos, M. Roussou, and M. Gkotzamanidou, The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma, Leukemia, vol.27, pp.423-429, 2013.

M. A. Dimopoulos, M. Roussou, and M. Gavriatopoulou, Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis, American Journal of Hematology, vol.91, pp.499-502, 2016.

K. C. Weisel, M. A. Dimopoulos, and P. Moreau, Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low -dose dexamethasone versus high -dose dexamethasone in refractory or relapsed and refractory multiple myeloma, Haematologica, vol.101, pp.872-878, 2016.

M. Dimopoulos, K. Weisel, and N. Van-de-donk, Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.36, pp.2035-2043, 2018.

A. Waszczuk-gajda, Z. Lewandowski, and J. Drozd-soko?owska, Autologous peripheral blood stem cell transplantation in dialysis-dependent multiple myeloma patients -DAUTOS Study of the Polish Myeloma Study Group, European Journal of Haematology, 2018.

S. V. Glavey, M. A. Gertz, and A. Dispenzieri, Long-term outcome of patients with multiple [corrected] myeloma-related advanced renal failure following auto-SCT, Bone Marrow Transplantation, vol.48, pp.1543-1547, 2013.

W. F. Clark, A. K. Stewart, and G. A. Rock, Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial, Annals of Internal Medicine, vol.143, pp.777-784, 2005.

X. Yu, L. Gan, Z. Wang, B. Dong, and X. Chen, Chemotherapy with or without plasmapheresis in acute renal failure due to multiple myeloma: a meta-analysis, International Journal of Clinical Pharmacology and Therapeutics, vol.53, pp.391-397, 2015.

F. Bridoux, P. Carron, and B. Pegourie, Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial, JAMA, vol.318, pp.2099-2110, 2017.

A. Granger-vallée, L. Chenine, and H. Leray-moragues, Online high-efficiency haemodiafiltration achieves higher serum free light chain removal than high-flux haemodialysis in multiple myeloma patients: preliminary quantitative study. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association, European Renal Association, vol.26, pp.3627-3633, 2011.

L. Kleeberg, S. Morgera, and J. C. , Novel renal replacement strategies for the elimination of serum free light chains in patients with kappa light chain nephropathy, European Journal of Medical Research, vol.14, pp.47-54, 2009.

S. Pasquali, F. Iannuzzella, and M. Corradini, A novel option for reducing free light chains in myeloma kidney: supra-hemodiafiltration with endogenous reinfusion (HFR), Journal of Nephrology, vol.28, pp.251-254, 2015.

P. Fabbrini, S. Sirtori, and E. Casiraghi, Polymethylmethacrylate membrane and serum free light chain removal: enhancing adsorption properties, Blood Purification, vol.35, issue.2, pp.52-58, 2013.

N. Raje, E. Terpos, and W. Willenbacher, Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, doubledummy, randomised, controlled, phase 3 study, The Lancet. Oncology, vol.19, pp.370-381, 2018.

T. R. Spitzer, M. Sykes, and N. Tolkoff-rubin, Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease, Transplantation, vol.91, pp.672-676, 2011.

B. G. Durie and S. E. Salmon, A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival, Cancer, vol.36, pp.842-854, 1975.

M. Courant, S. Md, . Orazio, A. Phd, . Monnerau et al., Hôpital Pellegrin, vol.33000

A. Monnereau, L. Remontet, M. Maynadié, F. Binder-foucard, A. Belot et al., Estimation nationale de l'incidence des cancers en France entre 1980 et 2012. Partie 2 -Hémopathies malignes

M. A. Dimopoulos, E. Terpos, and A. Chanan-khan, Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.28, pp.4976-4984, 2010.

D. J. Tsakiris, V. S. Stel, and P. Finne, Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or lightchain deposit disease: an ERA-EDTA Registry study. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association, European Renal Association, vol.25, pp.1200-1206, 2010.

F. Evison, J. Sangha, and P. Yadav, A population-based study of the impact of dialysis on mortality in multiple myeloma, British Journal of Haematology, vol.180, pp.588-591, 2018.

C. A. Hutchison, V. Batuman, and J. Behrens, The pathogenesis and diagnosis of acute kidney injury in multiple myeloma, Nature Reviews. Nephrology, vol.8, pp.43-51, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00696471

K. Uttervall, A. D. Duru, and J. Lund, The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment, PloS One, vol.9, p.101819, 2014.

A. J. Cowan, C. Allen, and A. Barac, Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study, JAMA Oncology, 2016.

J. F. Piccirillo, R. M. Tierney, I. Costas, L. Grove, and E. L. Spitznagel, Prognostic importance of comorbidity in a hospital-based cancer registry, JAMA, vol.291, pp.2441-2447, 2004.

S. V. Rajkumar, M. A. Dimopoulos, and A. Palumbo, International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, The Lancet. Oncology, vol.15, pp.538-548, 2014.

B. G. Durie and S. E. Salmon, A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival, Cancer, vol.36, pp.842-854, 1975.

M. A. Dimopoulos, P. Sonneveld, and N. Leung, International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.34, pp.1544-1557, 2016.

S. Kumar, B. Paiva, and K. C. Anderson, International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, The Lancet. Oncology, vol.17, pp.328-346, 2016.

A. Palumbo, H. Avet-loiseau, and S. Oliva, Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group, Journal, p.78

, Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.33, pp.2863-2869, 2015.

H. J. Kim, M. P. Fay, E. J. Feuer, and D. N. Midthune, Permutation tests for joinpoint regression with applications to cancer rates, Statistics in Medicine, vol.19, pp.335-351, 2000.

M. P. Perme, J. Stare, and J. Estève, On Estimation in Relative Survival, Biometrics, vol.68, pp.113-120, 2012.

K. Pavli? and M. P. Perme, On comparison of net survival curves, BMC medical research methodology, vol.17, p.79, 2017.

I. Turesson, M. Bjorkholm, C. H. Blimark, S. Kristinsson, R. Velez et al., Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival, European Journal of Haematology, 2018.

P. V. Sakhuja, V. Jha, and S. Varma, Renal Involvement in Multiple Myeloma: A 10-Year Study, Renal Failure, vol.22, pp.465-477, 2000.

J. Bartoszko, T. Panzarella, and C. J. Mcnamara, Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study, Clinical Lymphoma, Myeloma & Leukemia, vol.17, pp.774-781, 2017.

S. V. Rajkumar, Updated Diagnostic Criteria and Staging System for Multiple Myeloma, Annual Meeting, vol.35, pp.418-423, 2016.

A. K. Salahudeen, S. M. Doshi, T. Pawar, G. Nowshad, A. Lahoti et al., Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center, Clinical journal of the American Society of Nephrology: CJASN, vol.8, pp.347-354, 2013.

S. Uchino, R. Bellomo, D. Goldsmith, S. Bates, and C. Ronco, An assessment of the RIFLE criteria for acute renal failure in hospitalized patients, Critical Care Medicine, vol.34, pp.1913-1917, 2006.

C. Scheid, P. Sonneveld, and I. Schmidt-wolf, Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial, Haematologica, vol.99, pp.148-154, 2014.

A. Decourt, B. Gondouin, and J. C. Delaroziere, Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis, Clinical journal of the American Society of Nephrology: CJASN, vol.11, pp.431-441, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01482660

M. A. Dimopoulos, M. Roussou, and M. Gavriatopoulou, Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis, American Journal of Hematology, vol.91, pp.499-502, 2016.

, % (1) ?2-microglobulin >5.5mg/L, No./total (%) LDH level above the upper limit of normal, No./total (%) Albumin, median (IQR), g/L C-reactive protein, median (IQR), mg/L Cytogenetics, No./total (%) -Standard risk -High risk (2) , median (IQR), µmol/L eGFR, median (IQR), mL/min/1.73m 2 (3) Ratio of urine protein to creatinine, median (IQR), mg/mmoL, Serum involved-free light chain level, median (IQR), mg/L Bone marrow plasma cells, median (IQR)

, AKI: acute kidney injury. eGFR: estimated glomerular filtration rate. IQR: interquartile range. LDH : lactate dehydrogenase. MGUS: monoclonal gammopathy of undetermined significance. NA: non-available data. R-ISS: revised international staging system SMM: smoldering multiple myeloma

, Presence of at least one of the following abnormalities: del(17p), t(4;14) or t(14;16). (3) Calculated from the Modified Diet in Renal Disease formula. (4) Nonsteroidal anti-inflammatory, bisphosphonates, Data from the initial diagnosis were considered for relapsing/refractory multiple myeloma cases

, Serment d'Hippocrate

, Au moment d'être admis à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Admis dans l'intimité des personnes, je tairai les secrets qui me seront confiés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses

, que je sois déshonoré et méprisé si j'y manque